AU2009314336B2 - P70 S6 kinase inhibitor and EGFR inhibitor combination therapy - Google Patents

P70 S6 kinase inhibitor and EGFR inhibitor combination therapy Download PDF

Info

Publication number
AU2009314336B2
AU2009314336B2 AU2009314336A AU2009314336A AU2009314336B2 AU 2009314336 B2 AU2009314336 B2 AU 2009314336B2 AU 2009314336 A AU2009314336 A AU 2009314336A AU 2009314336 A AU2009314336 A AU 2009314336A AU 2009314336 B2 AU2009314336 B2 AU 2009314336B2
Authority
AU
Australia
Prior art keywords
trifluoromethyl
fluoro
phenyl
imidazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2009314336A
Other languages
English (en)
Other versions
AU2009314336A1 (en
Inventor
Sandaruwan Geeganage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2009314336A1 publication Critical patent/AU2009314336A1/en
Application granted granted Critical
Publication of AU2009314336B2 publication Critical patent/AU2009314336B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009314336A 2008-11-11 2009-11-04 P70 S6 kinase inhibitor and EGFR inhibitor combination therapy Expired - Fee Related AU2009314336B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327608P 2008-11-11 2008-11-11
US61/113,276 2008-11-11
PCT/US2009/063189 WO2010056575A1 (en) 2008-11-11 2009-11-04 P70 s6 kinase inhibitor and egfr inhibitor combination therapy

Publications (2)

Publication Number Publication Date
AU2009314336A1 AU2009314336A1 (en) 2010-05-20
AU2009314336B2 true AU2009314336B2 (en) 2013-09-12

Family

ID=41664868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009314336A Expired - Fee Related AU2009314336B2 (en) 2008-11-11 2009-11-04 P70 S6 kinase inhibitor and EGFR inhibitor combination therapy

Country Status (11)

Country Link
US (1) US8334293B2 (cg-RX-API-DMAC7.html)
EP (1) EP2355821A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012508240A (cg-RX-API-DMAC7.html)
KR (1) KR20110075015A (cg-RX-API-DMAC7.html)
CN (1) CN102209538B (cg-RX-API-DMAC7.html)
AU (1) AU2009314336B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921888A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743295A1 (cg-RX-API-DMAC7.html)
EA (1) EA018624B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005002A (cg-RX-API-DMAC7.html)
WO (1) WO2010056575A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746756T3 (es) 2013-03-11 2020-03-06 Merck Patent Gmbh Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa
EP2777707A1 (en) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Method of Treating Brain Tumors
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
EP3125885B1 (en) * 2014-04-04 2021-06-30 Astrazeneca AB Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
US11806326B2 (en) 2018-01-29 2023-11-07 Jonathan Sackner-Bernstein Methods for dopamine modulation in human neurologic diseases
DE102018205152A1 (de) 2018-04-05 2019-10-10 Glatt Ingenieurtechnik Gmbh Verfahren und Reaktor zur Herstellung von Partikeln

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047754A2 (en) * 2005-10-18 2007-04-26 George Mason Intellectual Properties, Inc. Mtor pathway theranostic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) * 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047754A2 (en) * 2005-10-18 2007-04-26 George Mason Intellectual Properties, Inc. Mtor pathway theranostic

Also Published As

Publication number Publication date
MX2011005002A (es) 2011-05-25
EP2355821A1 (en) 2011-08-17
EA201170682A1 (ru) 2011-10-31
KR20110075015A (ko) 2011-07-05
WO2010056575A1 (en) 2010-05-20
CA2743295A1 (en) 2010-05-20
BRPI0921888A2 (pt) 2015-12-29
US8334293B2 (en) 2012-12-18
JP2012508240A (ja) 2012-04-05
EA018624B1 (ru) 2013-09-30
CN102209538A (zh) 2011-10-05
US20110207752A1 (en) 2011-08-25
AU2009314336A1 (en) 2010-05-20
CN102209538B (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
ES2483726T3 (es) Inhibidores de la P70 S6 quinasa
US20240360085A1 (en) Glucose Uptake Inhibitors
AU2009314336B2 (en) P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
KR101398268B1 (ko) Ａｋｔ 억제제
AU2009314335B2 (en) P70 S6 kinase inhibitor and mTOR inhibitor combination therapy
WO2005046678A1 (en) Cancer treatment method
EP3797107B1 (en) Heterocondensed pyridone compounds and their use as idh inhibitors
WO2024229444A2 (en) Mutant kras inhibitors and uses thereof
US11654145B2 (en) Combination therapy involving diaryl macrocyclic compounds
US20130143834A1 (en) Cancer Treatment Method
CN114829370A (zh) 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
WO2008063853A2 (en) Cancer treatment method
WO2025166230A1 (en) PI3Kα INHIBITORS AND METHODS OF USE THEREOF
EA050570B1 (ru) Комбинация ингибитора бромодомена cbp/p300 и ингибитора kras для лечения рака

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application